US4296129A
Expired / Lapsed
US
⏱️ 0.0 years remaining
(Carboxyacylamino)phenylalkenamides and esters thereof as SRS-A antagonists
Assignee: Pfizer Inc
•
Filing: 1980-10-29
•
Granted: 1981-10-20
•
Expires: 2000-10-29
Abstract
Abstract Certain new propenamides and 2-butenamides having a (carboxyalkanamido)phenyl or a (carboxyalkenamido)phenyl group at the 3-position, and certain esters thereof, and their use for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (SRS-A) in a human subject. In particular, the compounds of the invention are useful for preventing and treating certain obstructive airways diseases, notably allergic bronchial asthma, allergic rhinitis and certain skin disorders, in human subjects.
Inventors
- 👤 Saul B. Kadin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 12:31
CPC Classifications
C; C07; C07C; C07C205/00; C07C205/49; C07C205/55; A; A61; A61P; A61P37/00; A61P37/08; C07C205/56
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
121 words
An alkenamide compound of the formula ##STR27## and the pharmaceutically-acceptable salts thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and -CH 2 -CH 2 -NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR28## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl.
Claim 2
Dependent Claim
121 words
An alkenamide compound of the formula ##STR27## and the pharmaceutically-acceptable salts thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and -CH 2 -CH 2 -NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR28## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl.
Claim 3
Dependent Claim
10 words
A compound according to claim 1, wherein X is cis-vinylene.
Claim 4
Dependent Claim
11 words
A compound according to claim 2, wherein R 1 is hydrogen.
Claim 5
Dependent Claim
12 words
A compound according to claim 3, wherein R 2 is said alkyl.
Claim 6
Dependent Claim
15 words
A compound according to claim 4, wherein R 5 and R 6 are both hydrogen.
Claim 7
Dependent Claim
21 words
A compound according to claim 5, wherein the two substituents on the phenyl ring have a meta relationship to each other.
Claim 8
Dependent Claim
11 words
The compound according to claim 6, wherein R 2 is decyl.
Claim 9
Dependent Claim
11 words
The compound according to claim 6, wherein R 2 is undecyl.
Claim 10
Dependent Claim
16 words
A compound according to claim 4, wherein R 5 is hydrogen and R 6 is methyl.
Claim 11
Dependent Claim
21 words
A compound according to claim 9, wherein the two substituents on the phenyl ring have a meta relationship to each other.
Claim 12
Dependent Claim
11 words
The compound according to claim 10, wherein R 2 is decyl.
Claim 13
Dependent Claim
11 words
The compound according to claim 10, wherein R 2 is 1-methyldecyl.
Claim 14
Dependent Claim
16 words
A compound according to claim 4, wherein R 5 is methyl and R 6 is hydrogen.
Claim 15
Dependent Claim
25 words
The compound according to claim 13, wherein R 2 is 1-methyldecyl and the substituents on the phenyl ring have a meta relationship to each other.
Claim 16
Dependent Claim
10 words
A compound according to claim 1, wherein X is ethylene.
Claim 17
Dependent Claim
11 words
A compound according to claim 15, wherein R 1 is hydrogen.
Claim 18
Dependent Claim
12 words
A compound according to claim 16, wherein R 2 is said alkyl.
Claim 19
Dependent Claim
34 words
The compound according to claim 17, wherein R 2 is decyl, R 5 is hydrogen, R 6 is methyl and the two substituents on the phenyl ring have a meta relationship to each other.
Claim 20
Dependent Claim
10 words
A compound according to claim 1, wherein X is ##STR29##
Claim 21
Dependent Claim
11 words
A compound according to claim 19, wherein R 1 is hydrogen.
Claim 22
Dependent Claim
12 words
A compound according to claim 20, wherein R 2 is said alkyl.
Claim 23
Dependent Claim
15 words
A compound according to claim 21, wherein R 7 and R 8 are each hydrogen.
Claim 24
Dependent Claim
34 words
The compound according to claim 22, wherein R 2 is decyl, R 5 is methyl, R 6 is hydrogen and the two substituents on the phenyl ring have a meta relationship to each other.
Claim 25
Dependent Claim
15 words
A compound according to claim 21, wherein R 7 and R 8 are both methyl.
Claim 26
Dependent Claim
34 words
The compound according to claim 24, wherein R 2 is decyl, R 5 and R 6 are both hydrogen, and the two substituents on the phenyl ring have a para relationship to each other.
Claim 27
Independent Claim
148 words
The method of antagonizing the effect of slow-reacting substance of anaphylaxis in a human subject, which comprises administering thereto a slow-reacting substance of anaphylaxis antagonizing amount of an alkenamide compound of the formula ##STR30## or a pharmaceutically-acceptable salt thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH 2 --CH 2 --NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR31## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl.
Claim 28
Independent Claim
148 words
The method of antagonizing the effect of slow-reacting substance of anaphylaxis in a human subject, which comprises administering thereto a slow-reacting substance of anaphylaxis antagonizing amount of an alkenamide compound of the formula ##STR30## or a pharmaceutically-acceptable salt thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH 2 --CH 2 --NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR31## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl.
Claim 29
Dependent Claim
152 words
A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and an alkenamide compound of the formula ##STR32## or a pharmaceutically-acceptable salt thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH 2 --CH 2 --NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR33## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl; and wherein the ratio of the pharmaceutically-acceptable carrier to the alkenamide compound is in the range from 1:6 to 6:1 by weight.
Claim 30
Dependent Claim
152 words
A pharmaceutical composition, which comprises a pharmaceutically-acceptable carrier and an alkenamide compound of the formula ##STR32## or a pharmaceutically-acceptable salt thereof; wherein R 1 is selected from the group consisting of hydrogen, alkyl having 1 to 4 carbons, and --CH 2 --CH 2 --NR 3 R 4 , wherein R 3 and R 4 are each alkyl having 1 to 3 carbons; R 2 is selected from the group consisting of alkyl having 8 to 15 carbons and cycloalkyl having from 6 to 12 carbons; R 5 and R 6 are selected from the group consisting of hydrogen and methyl; and X is selected from the group consisting of cis-vinylene, ethylene and ##STR33## wherein R 7 and R 8 are each selected from the group consisting of hydrogen and methyl; and wherein the ratio of the pharmaceutically-acceptable carrier to the alkenamide compound is in the range from 1:6 to 6:1 by weight.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-10-19 | 1985-04-20 | 1985-10-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-10-19 | 1989-04-20 | 1989-10-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-10-19 | 1993-04-20 | 1993-10-20 | $7700.00 | Window Closed / Lapsed |